We aimed to review the pharmacokinetics (PK) of intravenous busulfan in paediatric
patients, identify covariate factors influencing exposure, investigate evidence of changes in …

Introduction Busulfan is an alkylating agent widely used in the conditioning of hematopoietic
stem cell transplantation possessing a complex metabolism and a large interindividual and …

Busulfan (Bu) is a common component of conditioning regimens before hematopoietic stem
cell transplantation (HSCT) and is known for high interpatient pharmacokinetic (PK) …

Aims The aim of this study is to develop a population pharmacokinetic (PopPK) model for
intravenous busulfan in children that incorporates variants of GSTA1, gene coding for the …

Reaching target exposure of busulfan-based conditioning prior to hematopoietic stem cell
transplantation is vital for favorable therapy outcomes. Yet, a wide inter-patient and inter …

GSTA1 encodes a member of a family of enzymes that function to add glutathione to target
electrophilic compounds, including carcinogens, therapeutic drugs, environmental toxins …

Total-body irradiation (TBI) based conditioning prior to allogeneic hematopoietic stem cell
transplantation (HSCT) is generally regarded as the gold-standard for children> 4 years of …

Sinusoidal obstruction syndrome (SOS) is a potentially life-threatening complication after
hematopoietic stem cell transplantation (HSCT) or antineoplastic treatment without HSCT …

Background: Busulfan (Bu) is an alkylating agent used as part of the conditioning regimen in
pediatric patients before hematopoietic stem cell transplantation. Despite intravenous (IV) …

Abstract Background Busulfan (Bu) is the cornerstone of conditioning regimens prior to
hematopoietic stem cell transplantation, widely used in both adults and children for the …